OOIR: Observatory of International Research

Papers

(The H4-Index of Liver International is 39. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
MAFLD identifies patients with significant hepatic fibrosis better than NAFLD	305
Pathophysiological mechanisms of liver injury in COVID‐19	283
Prognostic accuracy of FIB‐4, NAFLD fibrosis score and APRI for NAFLD‐related events: A systematic review	192
Changing epidemiology of hepatocellular carcinoma in Asia	163
Prevalence of NAFLD, MAFLD and associated advanced fibrosis in the contemporary United States population	150
Hepatic macrophages: Key players in the development and progression of liver fibrosis	92
Progress towards hepatitis C virus elimination in high‐income countries: An updated analysis	91
Diet and exercise in NAFLD/NASH: Beyond the obvious	89
Disease burden and economic impact of diagnosed non‐alcoholic steatohepatitis in five European countries in 2018: A cost‐of‐illness analysis	86
Clinical impact of sexual dimorphism in non‐alcoholic fatty liver disease (NAFLD) and non‐alcoholic steatohepatitis (NASH)	81
Hepatitis E: An update on One Health and clinical medicine	79
The changing scenario of hepatocellular carcinoma in Italy: an update	74
The NAFLD‐MAFLD debate: Eminence vs evidence	68
Systematically comparing epidemiological and clinical features of MAFLD and NAFLD by meta‐analysis: Focusing on the non‐overlap groups	66
Exploring the landscape of steatotic liver disease in the general US population	62
PPAR‐γ‐induced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with NASH	61
Consensus recommendations for histological criteria of autoimmune hepatitis from the International AIH Pathology Group	61
Secondary sclerosing cholangitis as cause of persistent jaundice in patients with severe COVID‐19	59
Treatment and the prognosis of hepatocellular carcinoma in Asia	59
Characterization of the gut‐liver‐muscle axis in cirrhotic patients with sarcopenia	57
Incidence and risk factors of drug‐induced liver injury	54
Atezolizumab and bevacizumab combination compared with sorafenib as the first‐line systemic treatment for patients with unresectable hepatocellular carcinoma: A cost‐effectiveness analysis in China an	53
Fresh frozen plasma transfusion in acute variceal haemorrhage: Results from a multicentre cohort study	53
Gamma‐Glutamyl Transferase (γ‐GT) – an old dog with new tricks?	51
Ultra‐processed food is associated with features of metabolic syndrome and non‐alcoholic fatty liver disease	51

Efficacy and safety of givosiran for acute hepatic porphyria: 24‐month interim analysis of the randomized phase 3 ENVISION study	50
Clinical characteristics of COVID‐19 patients with hepatitis B virus infection — a retrospective study	49
Prognostic value of multiparametric magnetic resonance imaging, transient elastography and blood‐based fibrosis markers in patients with chronic liver disease	46
Clinical characteristics and management of 1572 patients with pyogenic liver abscess: A 12‐year retrospective study	45
2021 ISHEN guidelines on animal models of hepatic encephalopathy	45
Efficacy and safety of atezolizumab plus bevacizumab in Korean patients with advanced hepatocellular carcinoma	44
Lenvatinib versus sorafenib in first‐line treatment of unresectable hepatocellular carcinoma: An inverse probability of treatment weighting analysis	43
Sarcopenia in nonalcoholic fatty liver disease and all‐cause and cause‐specific mortality in the United States	42
Safety of direct oral anticoagulants in patients with advanced liver disease	41
Adipose tissue dysfunction and visceral fat are associated with hepatic insulin resistance and severity of NASH even in lean individuals	41
Ferroptosis and metabolic dysfunction‐associated fatty liver disease: Is there a link?	40
Seladelpar improved measures of pruritus, sleep, and fatigue and decreased serum bile acids in patients with primary biliary cholangitis	40
Terlipressin has stood the test of time: Clinical overview in 2020 and future perspectives	40
Circulating trimethylamine‐N‐oxide is associated with all‐cause mortality in subjects with nonalcoholic fatty liver disease	39
Association of genetic variations with NAFLD in lean individuals	39
Portal hypertension and hepatocellular carcinoma: Des liaisons dangereuses…	39
Management of NAFLD in primary care settings	39